Plus Therapeutics Inc (PSTV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $26.64M
Last updated: Nov 16, 2026 at 4:00 PM ET
Plus Therapeutics Inc (PSTV) Statistics
Plus Therapeutics (PSTV) has a market cap of $26.64M and an enterprise value of $29.61M. It kept -859.47% of revenue as net income over the last 12 months. Its share count is up 76.09% from a year earlier.
Total Valuation
Enterprise value is 11.16% above the market cap, as debt exceeds cash.
| Market Cap | $26.64M |
|---|---|
| Enterprise Value | $29.61M |
| Close (Nov 16, 2026) | $0.71 |
Key Dates
| Last Earnings Date | May 15, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 1.5x. Its year-end P/S ranged from 1.3x to 37.7x from 2016 to 2024.
| P/S Ratio | 1.5x |
|---|---|
| Forward P/S | 4.2x |
Price Statistics
The stock is down 94.53% over 52 weeks and trades 57.23% below its 50-day average.
| Beta (1Y) | 1.96 |
|---|---|
| 52-Week Change | -94.53% |
| 1-Month Change | -57.95% |
| 3-Month Change | -76.79% |
| 6-Month Change | -87.76% |
| 5-Year Change | -99.76% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -94.53% |
| Total Return (3Y CAGR) | -77.87% |
| Total Return (5Y CAGR) | -74.00% |
| Max Drawdown (1Y) | -96.83% |
| Max Drawdown (3Y) | -99.12% |
| Sharpe Ratio (1Y) | -2.35 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $1.66 |
| 200-Day Average | $4.31 |
| 52-Week Range | $2.90 to $23.43 |
| RSI (14 Days) | 32.3 |
| Average Volume (20 Days) | 2.25M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.61x current liabilities.
| Current Ratio | 0.61x |
|---|---|
| Quick Ratio | 0.60x |
Returns and Efficiency
Return on invested capital is -827.77% over the last 12 months.
| Return on Assets (ROA) | -248.54% |
|---|---|
| Return on Invested Capital (ROIC) | -827.77% |
| Asset Turnover | 0.23x |
| Receivables Turnover | 9.77x |
Scores
PSTV has an Altman Z-Score of -70.28, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -70.28 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $3.53M over the last 12 months is down 32.90% from the 12 months before.
| Revenue | $3.53M |
|---|---|
| Revenue Growth (YoY) | -32.90% |
| Gross Profit | $3.53M |
| Operating Income | -$29.37M |
| Pretax Income | -$30.32M |
| Net Income | -$30.32M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $879.00K |
|---|---|
| Total Debt | $3.85M |
| Net Debt | $2.97M |
| Net Debt Per Share | $0.39 |
| Working Capital | -$5.06M |
| Shareholder Equity | -$923.00K |
| Tangible Book Value | -$1.53M |
| Total Assets | $12.20M |
| Total Liabilities | $13.12M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.40M of capital spending, operating cash flow left -$28.70M of free cash flow.
| Operating Cash Flow | -$27.30M |
|---|---|
| Capital Expenditures | $1.40M |
| Free Cash Flow | -$28.70M |
| FCF Per Share | -$4.17 |
| Depreciation and Amortization | $572.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -832.57%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -832.57% |
| Pretax Margin | -859.47% |
| Net Margin | -859.47% |
| FCF Margin | -813.46% |
Dividends and Yields
PSTV does not pay a dividend. Its free cash flow yield is -530.60%.
| FCF Yield | -530.60% |
|---|---|
| Buyback Yield | -30.30% |
| Shareholder Yield | -30.30% |
Stock Splits
The last split was a 1-for-25 reverse split on Apr 2, 2026.
| Last Split Date | Apr 2, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Peer Position
Against 5 similar companies, PSTV has the lowest ROIC.
ROICPeer median -95.44%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| ROIC | -827.77% vs -95.44% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -32.90% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 91.62% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +91.62% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PSTV
What is PSTV's market cap?
Plus Therapeutics has a market cap of $26.64M. Its enterprise value, which adds debt and subtracts cash, is $29.61M.
How many shares of PSTV are outstanding?
Plus Therapeutics has 7.57M shares outstanding. The count is up 76.09% from a year earlier.
Does PSTV pay a dividend?
No. Plus Therapeutics does not pay a dividend.
How much debt does PSTV have?
Plus Therapeutics has $3.85M of total debt and $879.00K of cash and equivalents, a net debt position of $2.97M.
PSTV pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors